Screener
Tarsus Pharmaceuticals, Inc. TARS Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accounts payable | 23,410 | 269 |
| Accrued payroll and benefits | (5,892) | (4,212) |
| Other accrued liabilities | 28,754 | 13,334 |
| Net cash provided by (used in) operating activities | 36,571 | (50,038) |
| Cash Flows From Investing Activities: | ||
| Proceeds from maturities of marketable securities | 118,404 | 170,218 |
| Purchases of marketable securities | (129,201) | (255,273) |
| Purchases of property and equipment | (9,887) | (1,591) |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s operating cash flow?
- Tarsus Pharmaceuticals, Inc. (TARS) reported operating cash flow of $61.22M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s operating cash flow changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s operating cash flow increased by 308.3% year-over-year, from -$29.39M to $61.22M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s operating cash flow?
- Over 2 years (2022 to 2024), Tarsus Pharmaceuticals, Inc.'s operating cash flow has grown at a 30.1% compound annual growth rate (CAGR), from -$49.03M to -$83.03M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude